Immuron Hires Pullan for IMM-529 Partnership, Forecasts US$400M Sales
IMRN•Immuron engaged Pullan Consulting to secure a strategic partner for clinical development and commercialization of IMM-529, which has FDA approval for IND 32095 and will start a 60-subject Phase 2 trial in Australia. The company forecasts US$400 million annual IMM-529 revenue with potential upfront fees of US$1–50 million and milestones up to US$570 million.
1. Engagement with Pullan Consulting
Immuron has engaged Pullan Consulting, a life sciences advisory firm with 20 years of experience executing 5–12 partnering transactions annually, to identify and negotiate a strategic partner to advance IMM-529 through regulatory approval and commercialization.
2. FDA Approval and Phase 2 Trial Design
IMM-529 holds FDA approval for IND 32095 and is set to begin a randomized, double-blind Phase 2 trial in Australia under the CTN scheme, enrolling up to 60 subjects across three sites to assess safety, tolerability, and efficacy versus placebo alongside standard care.
3. Market Potential and Patient Population
The company projects US$400 million in annual IMM-529 revenues based on positioning at first recurrence, with an eligible patient population of approximately 98,000 and anticipated payer-restricted pricing for a polyclonal antibody therapy that decolonizes C. difficile and supports microbiome recovery.
4. Licensing Model and Deal Comparables
Immuron aims to license IMM-529 under a model featuring US$1–50 million upfront payments, US$25–570 million in development and sales milestones, and mid-to-high single-digit royalties, reflecting historical CDI partnerships with similar deal structures.
